An interventional study of HARMONI® Modular Intraocular Lens System and Intraoperative optic exchange in Cataract, Corneal Astigmatism and Aphakia, sponsored by ClarVista Medical. Completed at 2 sites in 2 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2020-06-22.
Sponsored by ClarVista Medical · Not applicable, Interventional, and Treatment
The purpose of this study was to demonstrate the safety and effectiveness of the HARMONI® Modular Intraocular Lens System with a toric optic in subjects with pre-existing corneal astigmatism in need of cataract surgery.
Subjects were implanted with the HARMONI® Modular Intraocular Lens System (HMIOL). The eye with the higher corneal astigmatism (study eye) was assigned to Cohort 1 and received the HARMONI® Modular Intraocular Lens System with a toric optic. The fellow eye was assigned to Cohort 2 and received the HARMONI® Modular Intraocular Lens System with a non-toric optic during primary implantation, which was replaced with the appropriate optic power (toric or non-toric) during an intraoperative exchange (IOE) procedure. A total of 7 study visits were planned, including a preoperative visit, operative visits for each eye, and 4 follow-up visits at 1 day, 1 week, 1 month, and 3 months postoperative. The total duration of participation for each subject was up to 6 months, which included a Day -90 to Day -0 preoperative period.
Alcon Research, LLC, acquired ClarVista Medical in 2017. This study was designed and conducted by ClarVista Medical, Inc. The study results were collected, analyzed, and provided by ClarVista Medical, Inc. to Alcon Research, LLC.
1,726 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's enrollment of 44 is below the median of 80 across 1,171 interventional studies indexed under Cataract.
Browse Cataract studies →ClarVista Medical is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria
Key Exclusion Criteria
Study eye: Primary implantation of HMIOL system with toric optic and no intraoperative optic exchange
Device: HARMONI® Modular Intraocular Lens System
Fellow eye: Primary implantation of HMIOL system with monofocal optic, followed by intraoperative optic exchange (toric or non-toric optic)
Device: HARMONI® Modular Intraocular Lens System · Procedure: Intraoperative optic exchange
Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
Also known as: HMIOL
Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
Also known as: IOE
Mean Manifest Refraction Cylinder (MRCYL) for Eyes Implanted With HMTIOL
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of added correction needed to compensate for any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number, with a less negative number indicating a lesser amount of added correction. No formal statistical hypothesis testing was planned.
Time frame: Month 1 postoperative, Month 3 postoperative
Mean Manifest Refraction Cylinder (MRCYL) Prediction Error (PE) for Eyes Implanted With HMTIOL
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. MRCYL PE was calculated as postoperative MRCYL adjusted to 6 meters minus MRCYL target residual refractive error (TRRE), with a lower absolute value indicating a more accurate cylinder power calculation. No formal statistical hypothesis testing was planned.
Time frame: Month 1 postoperative, Month 3 postoperative
Mean Reduction in Cylinder Power for Eyes Implanted With HMTIOL
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 preoperative), Month 3 postoperative
Mean Percent Reduction in Cylinder Power for Eyes Implanted With HMTIOL
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. Therefore, the cylindrical power percent reduction was the cylinder power reduction divided by the absolute value of preoperative magnitude of corneal cylinder (K) × 100. A higher number (greater percent reduction) indicates better astigmatism correction by the toric IOL. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 preoperative), Month 3 postoperative
Mean Manifest Refraction Spherical Equivalent (MRSE) Prediction Error (PE)
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. The manifest refraction spherical equivalent (MRSE) was calculated as follows: sphere + 1/2 cylinder, and measured in diopters (D). MRSE PE was calculated as postoperative MRSE adjusted to 6 meters minus MRSE target residual refractive error (TRRE). The lower the absolute number, the more accurate the IOL power calculation is. No formal statistical hypothesis testing was planned.
Time frame: Month 3 postoperative
Mean Absolute Rotation of IOL Meridian
IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees, with a lower number indicating less rotation. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 operative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Number of Eyes With Absolute Rotation of IOL Meridian by Visit - Cohort 1
IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees and is reported categorically. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 operative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Number of Eyes With Absolute Rotation of IOL Meridian by Visit - Cohort 2
IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees and is reported categorically. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 operative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit - Cohort 1
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with the correction obtained from manifest refraction testing. BCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 operative), Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit - Cohort 2
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with the correction obtained from manifest refraction testing. UCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 operative), Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit - Cohort 1
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with an optical infinity adjustment of +0.25 diopter (D). The Snellen fraction compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 operative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit - Cohort 2
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with an optical infinity adjustment of +0.25 diopter (D). The Snellen fraction compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
Time frame: Baseline (Day 0 operative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Number of Eyes With Preservation of BCDVA at Month 1 and Month 3
Preservation of BCDVA was defined in terms of lines lost when reading the ETDRS chart at each visit compared to the prior best-achieved BCDVA. Loss of \< 1 line included subjects with less than a 1 line loss, no change or improvement in BCDVA. No formal statistical hypothesis testing was planned.
Time frame: Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Number of Ocular Adverse Events Through Month 3
Ocular adverse events were identified as outlined in ISO 11979-2014 Annex B. No formal statistical hypothesis testing was planned.
Time frame: Up to Month 3 postoperative
Number of Device Deficiencies Post Implantation
A Device Deficiency (DD) was defined as a failure of the device to meet its performance specifications or expectations, or otherwise not perform as intended. This could include either a malfunction or damage to the device or any part thereof, regardless of the source of malfunction or damage, including user error, and regardless of the presence of injury (or lack thereof) to subject, user, or bystander. No formal statistical hypothesis testing was planned.
Time frame: Up to Month 3 postoperative
Number of Secondary Surgical Interventions, Other Than Intraroperative Optic Exchange and Rotational Adjustment of the Toric Optic in Cohort 2
A secondary surgical intervention (SSI) was defined as a surgical procedure that occurred after primary implantation and was conducted for the purpose of resolving residual refractive error (RRE) and optimizing visual outcomes. No formal statistical hypothesis testing was planned.
Time frame: Up to Month 3 postoperative
Percent Change in Endothelial Cell Count (ECC) at Month 3
High quality images of the corneal endothelium (the single layer of cells on the inner surface of the cornea) were taken at the investigative site and sent to an independent central reading center for evaluation. A negative percent change value may indicate a decrease in the ability of the endothelium to maintain its primary function. No formal statistical hypothesis testing was planned.
Time frame: Baseline (preoperative), Month 3 postoperative
This study was conducted at 1 site located in the Philippines and 1 site located in Mexico. Of the 44 subjects signing an informed consent, 12 failed to meet inclusion/exclusion criteria and 5 were withdrawn prior to implantation when the intraocular lens power was not available due to inventory restrictions.
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 27 | 27 |
| Completed | 27 | 27 |
| Not completed | 0 | 0 |
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of added correction needed to compensate for any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number, with a less negative number indicating a lesser amount of added correction. No formal statistical hypothesis testing was planned.
| diopter | Cohort 1 | Cohort 2 |
|---|---|---|
| Month 1 postoperative | -0.54 ± 0.32 | -0.75 ± 0.31 |
| Month 3 postoperative | -0.58 ± 0.42 | -0.72 ± 0.45 |
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. MRCYL PE was calculated as postoperative MRCYL adjusted to 6 meters minus MRCYL target residual refractive error (TRRE), with a lower absolute value indicating a more accurate cylinder power calculation. No formal statistical hypothesis testing was planned.
| diopter | Cohort 1 | Cohort 2 |
|---|---|---|
| Month 1 postoperative | -0.30 ± 0.28 | -0.53 ± 0.36 |
| Month 3 postoperative | -0.33 ± 0.33 | -0.44 ± 0.37 |
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. No formal statistical hypothesis testing was planned.
| diopter | Cohort 1 | Cohort 2 |
|---|---|---|
| Mean Reduction in Cylinder Power for Eyes Implanted With HMTIOL | 0.79 ± 0.56 | 0.53 ± 0.39 |
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. Therefore, the cylindrical power percent reduction was the cylinder power reduction divided by the absolute value of preoperative magnitude of corneal cylinder (K) × 100. A higher number (greater percent reduction) indicates better astigmatism correction by the toric IOL. No formal statistical hypothesis testing was planned.
| percent reduction | Cohort 1 | Cohort 2 |
|---|---|---|
| Mean Percent Reduction in Cylinder Power for Eyes Implanted With HMTIOL | 54.9 ± 29.3 | 39.5 ± 34.2 |
A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. The manifest refraction spherical equivalent (MRSE) was calculated as follows: sphere + 1/2 cylinder, and measured in diopters (D). MRSE PE was calculated as postoperative MRSE adjusted to 6 meters minus MRSE target residual refractive error (TRRE). The lower the absolute number, the more accurate the IOL power calculation is. No formal statistical hypothesis testing was planned.
| diopter | Cohort 1 | Cohort 2 |
|---|---|---|
| Mean Manifest Refraction Spherical Equivalent (MRSE) Prediction Error (PE) | 0.03 ± 0.45 | -0.12 ± 0.43 |
IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees, with a lower number indicating less rotation. No formal statistical hypothesis testing was planned.
| degrees | Cohort 1 | Cohort 2 |
|---|---|---|
| Rotation from operative to Day 1 | 1.8 ± 1.3 | 2.1 ± 1.4 |
| Rotation from operative to Week 1 | 2.4 ± 1.4 | 1.6 ± 1.7 |
| Rotation from operative to Month 1 | 3.1 ± 4.5 | 2.3 ± 1.5 |
| Rotation from operative to Month 3 | 3.2 ± 4.6 | 2.2 ± 1.6 |
IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees and is reported categorically. No formal statistical hypothesis testing was planned.
| eyes | Cohort 1 - Day 1 Postoperative | Cohort 1 - Week 1 Postoperative | Cohort 1 - Month 1 Postoperative | Cohort 1 - Month 3 Postoperative |
|---|---|---|---|---|
| Rotation from Operative ≤ 5 degrees | 22 | 23 | 23 | 22 |
| Rotation from Operative >5 degrees to ≤ 10 degrees | 0 | 0 | 0 | 0 |
| Rotation from Operative >10 degrees to ≤ 20 degree | 0 | 0 | 0 | 0 |
| Rotation from Operative > 20 degrees | 0 | 0 | 1 | 1 |
IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees and is reported categorically. No formal statistical hypothesis testing was planned.
| eyes | Cohort 2 - Day 1 Postoperative | Cohort 2 - Week 1 Postoperative | Cohort 2 - Month 1 Postoperative | Cohort 2 - Month 3 Postoperative |
|---|---|---|---|---|
| Rotation from Operative ≤ 5 degrees | 20 | 17 | 18 | 19 |
| Rotation from Operative >5 degrees to ≤ 10 degrees | 0 | 0 | 0 | 0 |
| Rotation from Operative >10 degrees to ≤ 20 degree | 0 | 0 | 0 | 0 |
| Rotation from Operative > 20 degrees | 0 | 0 | 0 | 0 |
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with the correction obtained from manifest refraction testing. BCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
| Percentage of eyes | Cohort 1 - Baseline (Day 0 Preoperative) | Cohort 1 - Week 1 Postoperative | Cohort 1 - Month 1 Postoperative | Cohort 1 - Month 3 Postoperative |
|---|---|---|---|---|
| 20/20 Snellen or Better | 22.2 | 66.7 | 59.3 | 70.4 |
| 20/25 Snellen or Better | 51.9 | 77.8 | 85.2 | 92.6 |
| 20/32 Snellen or Better | 70.4 | 96.3 | 100.0 | 96.3 |
| 20/40 Snellen or Better | 92.6 | 100.0 | 100.0 | 96.3 |
| Worse than 20/40 Snellen | 7.4 | 0.0 | 0.0 | 3.7 |
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with the correction obtained from manifest refraction testing. UCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
| percentage of eyes | Cohort 2 - Baseline (Day 0 Preoperative) | Cohort 2 - Week 1 Postoperative | Cohort 2 - Month 1 Postoperative | Cohort 2 - Month 3 Postoperative |
|---|---|---|---|---|
| 20/20 Snellen or Better | 23.1 | 76.9 | 73.1 | 76.9 |
| 20/25 Snellen or Better | 57.7 | 84.6 | 88.5 | 92.3 |
| 20/32 Snellen or Better | 76.9 | 96.2 | 92.3 | 100 |
| 20/40 Snellen or Better | 88.5 | 96.2 | 100.0 | 100.0 |
| Worse than 20/40 Snellen | 11.5 | 3.8 | 0.0 | 0.0 |
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with an optical infinity adjustment of +0.25 diopter (D). The Snellen fraction compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
| percentage of eyes | Cohort 1 - Baseline (Day 0 Preoperative) | Day 1 Postoperative | Cohort 1 - Week 1 Postoperative | Cohort 1 - Month 1 Postoperative | Cohort 1 - Month 3 Postoperative |
|---|---|---|---|---|---|
| 20/20 Snellen or Better | 3.7 | 48.1 | 44.4 | 40.7 | 40.7 |
| 20/25 Snellen or Better | 14.8 | 55.6 | 59.3 | 74.1 | 70.4 |
| 20/32 Snellen or Better | 14.8 | 77.8 | 88.9 | 92.6 | 92.6 |
| 20/40 Snellen or Better | 40.7 | 96.3 | 100.0 | 96.3 | 96.3 |
| Worse than 20/40 Snellen | 59.3 | 3.7 | 0.0 | 3.7 | 3.7 |
Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with an optical infinity adjustment of +0.25 diopter (D). The Snellen fraction compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.
| percentage of eyes | Cohort 2 - Baseline (Day 0 Preoperative) | Cohort 2 - Day 1 Postoperative | Cohort 2 - Week 1 Postoperative | Cohort 2 - Month 1 Postoperative | Cohort 2 - Month 3 Postoperative |
|---|---|---|---|---|---|
| 20/20 Snellen or Better | 0.0 | 46.2 | 53.8 | 42.3 | 34.6 |
| 20/25 Snellen or Better | 3.8 | 65.4 | 76.9 | 73.1 | 69.2 |
| 20/32 Snellen or Better | 11.5 | 65.4 | 84.6 | 88.5 | 84.6 |
| 20/40 Snellen or Better | 50.0 | 92.3 | 92.3 | 100.0 | 100.0 |
| Worse than 20/40 Snellen | 50.0 | 7.7 | 7.7 | 0.0 | 0.0 |
Preservation of BCDVA was defined in terms of lines lost when reading the ETDRS chart at each visit compared to the prior best-achieved BCDVA. Loss of \< 1 line included subjects with less than a 1 line loss, no change or improvement in BCDVA. No formal statistical hypothesis testing was planned.
| eyes | Cohort 1 - Month 1 Postoperative | Cohort 1 - Month 3 Postoperative | Cohort 2 - Month 1 Postoperative | Cohort 2 - Month 3 Postoperative |
|---|---|---|---|---|
| Loss < 1 line | 27 | 25 | 25 | 26 |
| Loss >= 1 lines | 0 | 2 | 1 | 0 |
| Loss >= 2 lines | 0 | 1 | 0 | 0 |
| Loss >= 3 lines | 0 | 0 | 0 | 0 |
| Loss >= 4 lines | 0 | 0 | 0 | 0 |
Ocular adverse events were identified as outlined in ISO 11979-2014 Annex B. No formal statistical hypothesis testing was planned.
| adverse event | Cohort 1 | Cohort 2 |
|---|---|---|
| Conjunctivitis viral | 1 | 0 |
| Cystoid macular oedema | 1 | 1 |
| Ciliary zonular dehiscence | 0 | 1 |
| Intraocular pressure increased | 0 | 1 |
| Iridocyclitis | 0 | 1 |
A Device Deficiency (DD) was defined as a failure of the device to meet its performance specifications or expectations, or otherwise not perform as intended. This could include either a malfunction or damage to the device or any part thereof, regardless of the source of malfunction or damage, including user error, and regardless of the presence of injury (or lack thereof) to subject, user, or bystander. No formal statistical hypothesis testing was planned.
| device deficiency | Cohort 1 - No Exchange | Cohort 2 - Intraoperative Exchange |
|---|---|---|
| Number of Device Deficiencies Post Implantation | 0 | 0 |
A secondary surgical intervention (SSI) was defined as a surgical procedure that occurred after primary implantation and was conducted for the purpose of resolving residual refractive error (RRE) and optimizing visual outcomes. No formal statistical hypothesis testing was planned.
| Secondary surgical interventions | Cohort 1 - No Exchange | Cohort 2 - Intraoperative Exchange |
|---|---|---|
| Number of Secondary Surgical Interventions, Other Than Intraroperative Optic Exchange and Rotational Adjustment of the Toric Optic in Cohort 2 | 0 | 0 |
High quality images of the corneal endothelium (the single layer of cells on the inner surface of the cornea) were taken at the investigative site and sent to an independent central reading center for evaluation. A negative percent change value may indicate a decrease in the ability of the endothelium to maintain its primary function. No formal statistical hypothesis testing was planned.
| percent change | Cohort 1 - No Exchange | Cohort 2 - Intraoperative Exchange |
|---|---|---|
| Percent Change in Endothelial Cell Count (ECC) at Month 3 | -12.5 ± 10.1 | -9.0 ± 10.3 |
Collected over Adverse events were collected from time of consent until study exit: Up to 6 months, including a Day -90 to Day -0 preoperative period and a 3-month postoperative period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| Cohort 2 | 0/27 (0%) | 1/27 (3.7%) | 0/27 (0%) |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| Eye complication associated with deviceGeneral disorders | 0/27 | 1/27 |
All implanted subjects
| Age, Continuous(years) | HMIOL |
|---|---|
| Mean | 67.4 ± 10.6 |
| Sex: Female, Male(Participants) | HMIOL |
|---|---|
| Female | 20 |
| Male | 7 |
| Race/Ethnicity, Customized(Participants) | HMIOL |
|---|---|
| Asian | 25 |
| Black | 0 |
| Caucasian | 0 |
| Other | 2 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ClarVista Medical